0001437749-20-002099.txt : 20200207
0001437749-20-002099.hdr.sgml : 20200207
20200207213846
ACCESSION NUMBER: 0001437749-20-002099
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200205
FILED AS OF DATE: 20200207
DATE AS OF CHANGE: 20200207
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mickle Travis C
CENTRAL INDEX KEY: 0001638365
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36913
FILM NUMBER: 20589165
MAIL ADDRESS:
STREET 1: 2656 CROSSPARK ROAD
STREET 2: SUITE 100
CITY: CORALVILLE
STATE: IA
ZIP: 52241
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: KEMPHARM, INC
CENTRAL INDEX KEY: 0001434647
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 205894398
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1180 CELEBRATION BOULEVARD, SUITE 103
CITY: CELEBRATION
STATE: FL
ZIP: 34747
BUSINESS PHONE: (321) 939-3416
MAIL ADDRESS:
STREET 1: 1180 CELEBRATION BOULEVARD, SUITE 103
CITY: CELEBRATION
STATE: FL
ZIP: 34747
FORMER COMPANY:
FORMER CONFORMED NAME: KEMPHARM INC
DATE OF NAME CHANGE: 20080507
4
1
rdgdoc.xml
FORM 4
X0306
4
2020-02-05
0001434647
KEMPHARM, INC
KMPH
0001638365
Mickle Travis C
C/O KEMPHARM, INC.
1180 CELEBRATION BOULEVARD, SUITE 103
CELEBRATION
FL
34747
1
1
1
President & CEO
Stock Option (right to buy)
0.374
2020-02-05
4
A
0
420000
0
A
2030-02-04
Common Stock
420000
420000
D
Grant to the Reporting Person of a stock option under the Issuer's 2014 Equity Incentive Plan (the "Plan"). 50% of the shares underlying the option will vest upon the approval by the U.S. Food and Drug Administration of a new drug application for the Company's product candidate, KP415. The remaining 50% of the shares underlying the option will vest upon the approval of a label for KP415 which includes 30 minute onset and 13-hour duration (the "30/13 Label") as defined in the KP415 License Agreement dated September 3, 2019. Each vesting event is contingent upon such optionee's continued employment with the Issuer at the relevant vesting date as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant.
/s/ Timothy J. Sangiovanni, Attorney-in-Fact for Travis C. Mickle
2020-02-07